AR048342A1 - FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) - Google Patents
FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)Info
- Publication number
- AR048342A1 AR048342A1 ARP050101197A ARP050101197A AR048342A1 AR 048342 A1 AR048342 A1 AR 048342A1 AR P050101197 A ARP050101197 A AR P050101197A AR P050101197 A ARP050101197 A AR P050101197A AR 048342 A1 AR048342 A1 AR 048342A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage forms
- pharmaceutical dosage
- glutamic acid
- fthalimidoetoxi
- acetile
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 5
- FDNPKSCZFOAEDF-SMDDNHRTSA-N (2r)-2-[[(2s)-2-[[2-[2-(1,3-dioxoisoindol-2-yl)ethoxy]acetyl]amino]propanoyl]amino]pentanedioic acid Chemical compound C1=CC=C2C(=O)N(CCOCC(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O)C(=O)C2=C1 FDNPKSCZFOAEDF-SMDDNHRTSA-N 0.000 title abstract 3
- 108010087378 N-(2-(2-phthalimidoethoxy)acetyl)-L-alanyl-D-glutamic acid Proteins 0.000 title abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a formas de dosificacion farmacéuticas que hacen posible el suministro controlado y/o dirigido de una sustancia activa a regiones seleccionadas del tracto gastrointestinal de seres humanos o animales. Las formas de dosificacion farmacéuticas comprenden a la sustancia activa de ácido N-(2-(2-ftalimido-etoxi)-acetil)-L-alanil-D-glutámico (designado como LK 423). Se dan a conocer métodos de tratamiento de enfermedades inflamatorias cronicas del tracto gastrointestinal de seres humanos y/o animales, mediante el uso de dichas formas de dosificacion farmacéuticas. Proceso para la preparacion de dichas formas de dosificacion farmacéuticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200400094 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048342A1 true AR048342A1 (es) | 2006-04-19 |
Family
ID=34964906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101197A AR048342A1 (es) | 2004-03-26 | 2005-03-28 | FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100183714A1 (es) |
| EP (1) | EP1734933B1 (es) |
| JP (1) | JP2007530492A (es) |
| CN (1) | CN1956707B (es) |
| AR (1) | AR048342A1 (es) |
| AT (1) | ATE468846T1 (es) |
| AU (1) | AU2005226927B2 (es) |
| BR (1) | BRPI0509271A (es) |
| CA (1) | CA2559685A1 (es) |
| DE (1) | DE602005021475D1 (es) |
| MY (1) | MY145329A (es) |
| PE (1) | PE20051163A1 (es) |
| RU (1) | RU2375047C2 (es) |
| TW (1) | TW200600121A (es) |
| WO (1) | WO2005092295A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8273376B2 (en) | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
| CA2678131A1 (en) * | 2006-11-17 | 2008-05-22 | Antoine Andremont | Colonic delivery using zn/pectin beads with a eudragit coating. |
| WO2009037264A2 (en) * | 2007-09-17 | 2009-03-26 | Da Volterra | Colonic delivery of antimicrobial agents |
| JP5719776B2 (ja) * | 2008-11-13 | 2015-05-20 | ノグラ ファーマ リミテッド | アンチセンス組成物およびその作製および使用 |
| MX391477B (es) * | 2015-06-01 | 2025-03-19 | Xeno Biosciences Inc | Metodos y composiciones para modular la microbiota intestinal y para manejar el peso |
| CN109562158A (zh) * | 2016-06-23 | 2019-04-02 | 纽特莱特公司 | 在动物中促进生长和提高饲料转化率的方法 |
| AU2017356350B2 (en) * | 2016-11-09 | 2024-02-29 | Engene, Inc. | Intestinal expression of programmed death ligand 1 |
| WO2018112240A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| WO2018112245A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| MX2019006867A (es) * | 2016-12-14 | 2020-01-13 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de integrina. |
| CN108968074B (zh) * | 2018-06-06 | 2021-09-28 | 福建省农业科学院农业工程技术研究所 | 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法 |
| KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
| AU2021241625B2 (en) | 2020-03-26 | 2025-04-24 | Nutrivert Inc. | Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05508631A (ja) * | 1990-05-04 | 1993-12-02 | イッサム・リサーチ・デベロップメント・カンパニー・オブ・ザ・ヒーブリュー・ユニバーシティー・オブ・エルサレム | 結腸用薬物送達システム |
| JP2773959B2 (ja) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| SI9011830B (sl) * | 1990-09-27 | 1999-12-31 | Univerza V Ljubljani, Fakulteta Za Farmacijo | Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo |
| DE19732903A1 (de) * | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
-
2005
- 2005-03-24 AU AU2005226927A patent/AU2005226927B2/en not_active Ceased
- 2005-03-24 WO PCT/EP2005/003175 patent/WO2005092295A1/en not_active Ceased
- 2005-03-24 US US10/599,289 patent/US20100183714A1/en not_active Abandoned
- 2005-03-24 AT AT05733297T patent/ATE468846T1/de active
- 2005-03-24 BR BRPI0509271-0A patent/BRPI0509271A/pt not_active IP Right Cessation
- 2005-03-24 DE DE602005021475T patent/DE602005021475D1/de not_active Expired - Fee Related
- 2005-03-24 MY MYPI20051274A patent/MY145329A/en unknown
- 2005-03-24 EP EP05733297A patent/EP1734933B1/en not_active Expired - Lifetime
- 2005-03-24 CN CN2005800168849A patent/CN1956707B/zh not_active Expired - Fee Related
- 2005-03-24 JP JP2007504366A patent/JP2007530492A/ja active Pending
- 2005-03-24 CA CA002559685A patent/CA2559685A1/en not_active Abandoned
- 2005-03-24 RU RU2006137660/15A patent/RU2375047C2/ru not_active IP Right Cessation
- 2005-03-28 AR ARP050101197A patent/AR048342A1/es unknown
- 2005-03-28 PE PE2005000349A patent/PE20051163A1/es not_active Application Discontinuation
- 2005-03-28 TW TW094109593A patent/TW200600121A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1956707B (zh) | 2010-12-29 |
| RU2375047C2 (ru) | 2009-12-10 |
| JP2007530492A (ja) | 2007-11-01 |
| ATE468846T1 (de) | 2010-06-15 |
| DE602005021475D1 (de) | 2010-07-08 |
| WO2005092295A1 (en) | 2005-10-06 |
| EP1734933A1 (en) | 2006-12-27 |
| PE20051163A1 (es) | 2006-02-21 |
| US20100183714A1 (en) | 2010-07-22 |
| RU2006137660A (ru) | 2008-05-10 |
| MY145329A (en) | 2012-01-31 |
| AU2005226927B2 (en) | 2010-09-23 |
| BRPI0509271A (pt) | 2007-09-04 |
| AU2005226927A1 (en) | 2005-10-06 |
| CN1956707A (zh) | 2007-05-02 |
| CA2559685A1 (en) | 2005-10-06 |
| EP1734933B1 (en) | 2010-05-26 |
| TW200600121A (en) | 2006-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30587A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus | |
| AR048342A1 (es) | FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423) | |
| CY1123162T1 (el) | Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης | |
| AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
| WO2008157103A3 (en) | Modified release solid or semi-solid dosage forms | |
| CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
| EA200970374A1 (ru) | Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом | |
| UY29321A1 (es) | Piperazinilureas y piperidinilureas como moduladores de hidrolasa de amida de ácidos grasos | |
| BRPI0924460A2 (pt) | composição farmacêutica para uso em oftalmologia médica e veterinária | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
| BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| CY1117174T1 (el) | ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ | |
| MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
| AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
| EA200800360A1 (ru) | Формуляции с высоким содержанием лекарства и дозированные формы | |
| AR048718A1 (es) | Uso de formulaciones de meloxicam en medicina veterinaria | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| NO20043792L (no) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
| EP4221704A4 (en) | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES | |
| CL2019002145A1 (es) | Composición farmacéutica que comprende betahistina. | |
| DE602004017164D1 (de) | Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten | |
| GT200600209A (es) | Tratamiento de enfermedades usando un sistema mejorado de expresion regulada | |
| UY37413A (es) | Formulaciones de liberación inmediata de oprozomib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |